Turkish Journal of Biology
Volume 38

Number 6

Article 15

1-1-2014

The effect of survivin gene promoter polymorphism on breast
cancer
MEHMET DENİZ ALTIPARMAK
CELAL İSMAİL BİLGİÇ
NÜZHET CENAP DENER
ESRA GÜNDÜZ
SİBEL YENİDÜNYA

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
ALTIPARMAK, MEHMET DENİZ; BİLGİÇ, CELAL İSMAİL; DENER, NÜZHET CENAP; GÜNDÜZ, ESRA;
YENİDÜNYA, SİBEL; ACAR, MURADİYE; ŞEN, MERAL; and GÜNDÜZ, MEHMET (2014) "The effect of
survivin gene promoter polymorphism on breast cancer," Turkish Journal of Biology: Vol. 38: No. 6, Article
15. https://doi.org/10.3906/biy-1405-78
Available at: https://journals.tubitak.gov.tr/biology/vol38/iss6/15

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The effect of survivin gene promoter polymorphism on breast cancer
Authors
MEHMET DENİZ ALTIPARMAK, CELAL İSMAİL BİLGİÇ, NÜZHET CENAP DENER, ESRA GÜNDÜZ, SİBEL
YENİDÜNYA, MURADİYE ACAR, MERAL ŞEN, and MEHMET GÜNDÜZ

This article is available in Turkish Journal of Biology: https://journals.tubitak.gov.tr/biology/vol38/iss6/15

Turkish Journal of Biology

Turk J Biol
(2014) 38: 858-866
© TÜBİTAK
doi:10.3906/biy-1405-78

http://journals.tubitak.gov.tr/biology/

Research Article

The effect of survivin gene promoter polymorphism on breast cancer
1

1,

1

2

3

Mehmet Deniz ALTIPARMAK , Celal İsmail BİLGİÇ *, Nüzhet Cenap DENER , Esra GÜNDÜZ , Sibel YENİDÜNYA ,
2
1
2,4
Muradiye ACAR , Meral ŞEN , Mehmet GÜNDÜZ
1
Department of General Surgery, Faculty of Medicine, Turgut Özal University, Ankara, Turkey
2
Department of Medical Genetics, Faculty of Medicine, Turgut Özal University, Ankara, Turkey
3
Department of Pathology, Faculty of Medicine, Turgut Özal University, Ankara, Turkey
4
Department of Otolaryngology, Faculty of Medicine, Turgut Özal University, Ankara, Turkey
Received: 28.05.2014

Accepted: 13.08.2014

Published Online: 24.11.2014

Printed: 22.12.2014

Abstract: Breast cancer is the most common malignant tumor in women and accounts for about 25% of all cancer diagnoses. Survivin
is a member of the apoptosis inhibitor protein family of antiapoptotic proteins. In our study, we investigated one of those, the survivin
gene promoter 31G/C polymorphism. Included in this study were 111 breast cancer patients who were operated on in our hospital
and 101 healthy female subjects. Blood samples from the healthy subjects and paraffin-embedded tissue samples from the patients
were used for DNA extraction and subsequent genetic analysis. PCR-RFLP was used for genotype analysis. We established the
clinicopathologic characteristics of patients. No significant difference was found between survivin 31G/C promoter polymorphism
of tumor characteristics and breast cancer. Between the control and breast cancer groups, survivin promoter polymorphism 31G/C
differences were not significantly different (P = 0.058). The risk of developing cancer, having the relevant GC or CC genotype, is 1.413
times higher than those having genotype GG (95% confidence interval: 1.040 to 1.918). Carrying the C allele was statistically significant
in terms of susceptibility to breast cancer. In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is
recommended based on the results of this study.
Key words: Breast cancer, apoptosis inhibitor protein, survivin, survivin gene promoter polymorphism, SNP

1. Introduction
Breast cancer is the most common malignant tumor
in women and accounts for about 25% of all cancer
diagnoses (Liu et al., 2014) and its incidence continues to
increase. Although signiﬁcant progress in the diagnosis
and treatment of breast cancer has been achieved over the
past several decades, it remains the second highest cause
of cancer-related deaths in women (Christensen et al.,
2006). The early identification of high-risk women is an
important issue because of the availability of medical and
surgical treatment options for breast cancer (Visvanathan
et al., 2009). A new gene profiling method has recently
been introduced as a powerful tool for predicting the
clinical outcomes of women with breast cancer.
Dysregulation of the balance between cell proliferation
and cell death contributes to carcinogenesis (including
the development and progression of breast cancer) by
prolonging cell survival, promoting the accumulation of
transforming mutations, and enhancing cell resistance to
chemotherapy (Bayram et al., 2011). Survivin is a member
of the inhibitor of apoptosis protein family, and is thought
* Correspondence: drismailbilgic@gmail.com
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to inhibit apoptosis and regulate mitosis. It has unique
properties, with bifunctional roles as a cell-cycle regulator
and an apoptosis inhibitor (Altieri, 2003). Although
survivin is strongly expressed in embryonic and fetal organs,
it is undetectable in most terminally differentiated normal
adult tissues (Ambrosini et al., 1997). However, survivin is
overexpressed in various cancers, including lung, breast,
colon, stomach, esophageal, pancreatic, bladder, uterine,
and ovarian cancers; large-cell non-Hodgkin’s lymphoma;
leukemia; neuroblastoma; melanoma; and nonmelanoma
skin cancer, compared with its expression in normal
tissues (Gazouli et al., 2009).
The survivin gene in humans spans 14.7 kb, and is located
in the telomeric region of chromosome 17q25 (Ambrosini
et al., 1998). Several single-nucleotide polymorphisms
(SNPs) have been identified within the promoter region
of the survivin gene. A polymorphism at position –31
promoter region, which involves the substitution G > C
(rs 9904341), is the most frequently documented SNP.
This polymorphism is located in a cell-cycle-dependent
element and the cell-cycle homology region repressor
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binding motif in the promoter region. The G > C mutation
correlates with the increased expression of survivin at
both the transcriptional and translational levels (Yazdani
et al., 2012). Several case–control studies have examined
the association between the –31G > C polymorphism
and the risk of cancer (Srivastava et al., 2012), including
nasopharyngeal carcinoma (Yang et al., 2009), esophageal
cancer (Upadhyay et al., 2011), gastric cancer (Yang et
al., 2009; Borges et al., 2011), hepatocellular carcinoma
(Bayram et al., 2011), pancreatic cancer (Theodoropoulos
et al., 2010), and urothelial carcinoma (Wang et al., 2009),
but the results are controversial.
Because of the critical role of survivin in
carcinogenesis and considering the prognostic and
therapeutic implications (Ambrosini et al., 1997), we
evaluated the correlation between this polymorphism
and clinicopathologic characteristics of patients. We also
evaluated the predisposition in breast cancer patients
having this polymorphism. To the best of our knowledge,
no study has yet determined the association between the
–31G > C polymorphism in the survivin gene and the risk
of breast cancer.
2. Materials and methods
2.1. Study design and patients
After approval was obtained from the Clinical Research
Ethics Board of Turgut Özal University School of Medicine,
111 patients with a diagnosis of invasive breast carcinoma
who had undergone surgery at the Department of General
Surgery, Turgut Özal University School of Medicine
between January 2004 and May 2011 were retrospectively
recruited and 101 healthy females subjects having no
history or diagnosis of cancer or genetic disease and aged
≥30 years were recruited from among individuals who
had visited the hospital for a physical examination. In the
cancer group, we excluded patients with systemic disease
at baseline, patients receiving neoadjuvant chemotherapy,
patients with pure in situ carcinoma, and patients missing
during the follow-up period.
After informed consent was obtained from all the
participants, blood samples were collected from the
healthy subjects for genetic analysis. Paraffin-embedded
tissue samples from the women with breast cancer were
stored at the Department of Pathology in our faculty and
were used for genetic analysis. The genetic studies were
conducted at the Genetics Laboratory of the Medical
Genetics Department.
We retrieved from our breast cancer database the age,
age at menarche, menopausal status, estrogen hormone
use, breastfeeding status, smoking status, family history
of breast cancer, tumor type, tumor size, tumor grade,
lymphatic-duct invasion, vascular invasion, perineural
invasion, multifocal/multicentric tumor presence,

lymphatic metastasis presence, number of metastatic
lymph nodes, estrogen/progesterone receptor status,
C-erbB2 status, and the recurrence and survival data for
each woman with breast cancer.
2.2. DNA isolation from paraffin-embedded tissue blocks
DNA was isolated and purified from paraffin-embedded
tissue blocks using the PureLink Genomic DNA Mini Kit
(Invitrogen, Carlsbad, CA, USA) and was stored at –20 °C
for PCR analysis.
2.3. DNA isolation from peripheral blood
DNA was isolated from peripheral blood samples from the
healthy women using the phenol–chloroform method and
was stored at –20 °C.
2.4. DNA amplification
To detect the –31G > C (rs 9904341) polymorphism
in the survivin gene, a 151 bp region was
amplified
using
the
following
primers:
5′
-AAGAGGGCGTGCGCTCCCGACA - 3′ (forward) and
5′ - GAGATGCGGTGGTCCTTGAGAAA - 3′ (reverse).
Primers were designed using the NCBI/Primer-BLAST
database. For the polymerase chain reaction (PCR) 2 μL
of DNA (150 ng/µL) solution in a total volume of 25 μL,
2.5 μL of 10X Taq (NH4) SO2 buffer, 2.5 mM MgCl2, 100
μM each dNTP, and 0.5 μL of 20 pmol each primer, 1 U
of Taq DNA polymerase, and 16.3 μL of dH2O were used.
The conditions for PCR were as follows: denaturation at 94
°C for 5 min; denaturation at 94 °C for 30 s, annealing at
62.2 °C for 30 s, and elongation at 72 °C for 1 min, which
was repeated for 35 cycles; final elongation was at 72 °C
for 5 min.
2.5. Agarose gel electrophoresis
To check whether the PCR products were successfully
amplified, they were run on 3% agarose gel (Invitrogen)
in 1X Tris–acetic acid–EDTA buffer. For electrophoresis,
5 µL of the PCR products were mixed with 1 µL of 6X
loading dye and the samples were loaded into the wells.
Electrophoresis was performed at 110 V for 15 min, after
which the PCR products were visualized with an ultraviolet
(UV) transilluminator (Figure 1).
2.6. DNA digestion and detection of the survivin –31G
> C (rs9904341) polymorphism (restriction fragment
length polymorphism (RFLP) analysis)
The DNA samples were digested using the Msp1 restriction
enzyme (FastDigest; Thermo Scientific, Waltham, MA,
USA). This enzyme digested the 151-bp DNA sequence
into 2 fragments (90 and 61 bp) by cutting the C base
at the polymorphic site. After digestion, 5 µL of the
restricted DNA was mixed with 1 µL of 6X loading dye.
The samples were then loaded into individual wells of an
agarose gel and separated electrophoretically at 100 V for
30 min, before visualization with a UV transilluminator.
To confirm the genotype at position –31, DNA sequencing
was performed.
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Figure 1. Patient group of PCR amplification products by agarose gel electrophoresis.
– C is negative control, 100 bp marker is used for product size, and the numbers in the
lanes indicate the patients’ PCR products followed by separation on 3.0% agarose gel.

2.7. Sequence analysis
Five representative samples were sequenced by ABI 3130
system. Survivin PCR products of several samples were
exposed to ExoSAP IT treatment (GML A.G., Wallerau,
Switzerland). Then sequence-specific PCRs were performed
on these samples followed by DNA precipitation and they
were run on an ABI 3130 sequencer.
3. Statistical analysis
The data were analyzed using SPSS for Windows version
16.0 (SPSS Inc., Chicago, IL, USA). Intervals and continuous
data are expressed as means ± standard deviations,
whereas categorical variables are expressed as numbers of
observations and percentages. The significance of differences

between the 2 groups was evaluated with Student’s t test
for continuous variables, whereas categorical variables
were compared using Pearson’s chi-squared test, Fisher’s
decisive chi-squared test, or the likelihood ratio test.
4. Results
A total of 111 patients with breast cancer and 101 controls
were enrolled in this study. There were no significant
differences between the 2 groups in terms of their age
at menarche, menopausal age, lactation status, smoking
history, or family history of breast cancer, which suggests
that our matching of the demographic characteristics was
satisfactory. The demographic and clinical characteristics
of both groups are shown in Table 1.

Table 1. The demographic and clinical characteristics of both groups.
Variables

Patient group
(n =111)

Healthy control group
(n = 101)

P value

Age

52.9 ± 14.3

40.2 ± 7.3

<0.001

Age of menarche

13.3 ± 1.2

13.2 ± 1.5

0.542

Age of menopause

47.9 ± 5.6

44.1 ± 9.0

0.120

Postmenopausal patients

64 (57.7%)

13 (12.9%)

<0.001

Hormonal therapy

26 (23.4%)

54 (53.5%)

<0.001

History of lactation

102 (91.9%)

89 (88.1%)

0.358

Smoking habits

0.286

No

93 (83.8%)

77 (76.2%)

Yes

17 (15.3%)

21 (20.8%)

Presence of previous smoking habits

1 (0.9%)

3 (3.0%)

Family history

860

0.166

Absent

88 (79.3%)

87 (86.1%)

1st degree relatives

12 (10.8%)

4 (4.0%)

2nd degree relatives

11 (9.9%)

10 (9.9%)
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We detected all 3 genotypes in our groups (Figures 2a
and b). There was a slight difference in the prevalence of
the survivin promoter polymorphism (–31G > C) between
the 2 groups, although the P value (P = 0.058) slightly
exceeded the threshold for statistical significance (i.e. P <
0.05). Notably, the combined prevalence of the GC and CC
genotypes (GC + CC), reflecting the prevalence of the C
allele, was significantly greater in the breast cancer group
than in the control group (P = 0.023), with rates of 59%
and 38%, respectively. These results imply that the C allele
at position –31 in the promoter region of the survivin gene

increases an individual’s susceptibility to breast cancer.
The distributions of the subjects in the breast cancer
and control groups according to the survivin promoter
polymorphism are shown in Table 2.
The risk of developing cancer was 1.413 times higher
in patients with the GC or CC genotype (GC + CC) than
in patients with the GG genotype, and this difference was
statistically significant (95% CI: 1.040–1.918; Table 3).
In the breast cancer group, the GG genotype was
present in 52 patients, whereas the GC + CC genotype was
present in 59 patients. There were no significant differences

Figure 2a. Genotyping of survivin –31G >C polymorphism by PCR-RFLP analysis
followed by separation on 3% agarose gel. Lane 1 is 50 bp marker; lanes 2 and 11 are
CC genotype; lanes 3 and 8 are GG genotype; lanes 4–7, 9, and 10 are GC genotype.

Figure 2b. Electropherogram image of heterozygous polymorphisms of surviving (GC)
genotype .
Table 2. The distributions of the subjects in the breast cancer and control groups
according to the survivin promoter polymorphism.
Patient group

Healthy control group

(n = 111)

(n = 101)

GG

52 (46.8%)

63 (62.4%)

GC

46 (41.4%)

32 (31.7%)

CC

13 (11.8%)

6 (5.9%)

GG

52 (46.8%)

63 (62.4%)

GC+CC

59 (53.2%)

38 (37.6%)

Survivin 31GC

Survivin

P value
0.058

0.023
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Table 3. Presence of GC+CC polymorphism and odds ratio.
Survivin promoter
polymorphism

Healthy control group
(n = 101)

Patient group
(n = 111)

Odds ratio
(95% confidence interval)

GC+CC

38 (37.6%)

59 (53.2%)

1.413 (1.040–1.918)

between these 2 groups in terms of age, menopausal
age, age at last birthday, hormone therapy, duration of
hormone therapy, history of lactation, smoking history,
family history of breast cancer, or the patient’s relationship
to family members with a history of breast cancer (Table 4).
In terms of the histopathological characteristics of
the breast cancer specimens, we found no significant
differences between the GG and GC + CC genotypes
in terms of multifocality/multicentricity, tumor
diameter (mm), tumor stage (TNM), histological
grade, lymphovascular invasion, perineural invasion,
presence of lymphatic metastasis, number of metastatic
lymph nodes, presence of an extensive intraductal
component, or extracapsular perinodal invasion.
There were no significant differences between these
2 groups in terms of the incidence of invasive ductal
carcinoma or invasive lobular carcinoma. There were
also no differences in the rates of estrogen receptor,
progesterone receptor, or C-erbB2 positivity (Table 5).
Furthermore, there were no differences between the 2

groups in the local recurrence and distant recurrence
rates, the median time to relapse in patients with
recurrence.
5. Discussion
Survivin is an antiapoptotic protein belonging to the
inhibitor of apoptosis protein family. It is a bifunctional
protein that regulates cell division and suppresses
apoptosis. Survivin is highly expressed in various human
malignancies, but its expression is very low or below the
level of detection in normal adult tissues (Ambrosini
et al., 1998; Yazdani et al., 2012). Survivin is usually
expressed in the G2/M phase of the cell cycle, when it
is thought to disrupt the apoptosis signaling pathways
and to promote the survival of abnormal cells, offering
a significant advantage to tumor cells overexpressing
survivin (Upadhyay et al., 2011). The elevated expression
of survivin is thought to be a negative prognostic factor
for tumors and its overexpression is reported to be
associated with shortened survival (Altieri, 2003). Many

Table 4. The demographic and clinical characteristics of GG and GC + CC genotype groups in
breast cancer patients.
Variables

GG
(n = 52)

GC+CC
(n = 59)

P value

Age

51.4 ± 12.9

54.3 ± 15.4

0.287

Age of menopause

48.3 ± 7.4

47.6 ± 4.0

0.787

Postmenopausal patients

28 (53.8%)

36 (61.0%)

0.445

Presence of hormonal therapy

9 (17.3%)

17 (28.8%)

0.214

Duration of hormonal therapy (months)

12.5±9.0

38.9±48.9

0.075

History of lactation

47 (90.4%)

55 (93.2%)

0.732

Smoking habits

862

0.455

No

45 (86.5%)

48 (81.4%)

Yes

7 (13.5%)

10 (16.9%)

Presence of previous smoking habits

-

1 (1.7%)

Family history

12 (23.1%)

11 (18.6%)

Absent

40 (76.9%)

48 (81.4%)

1st degree relatives

5 (9.6%)

7 (11.9%)

2nd or more degree relatives

7 (13.5%)

4 (6.8%)

0.565
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Table 5. The pathological characteristics of GG and GC + CC genotype groups in breast cancer patients.
Variables

GG (n = 52)

GC+CC (n = 59)

P value

Multifocal–multicentric

29 (55.8%)

25 (42.4%)

0.159

Unifocal

23 (44.2%)

34 (57.6%)

Invasive ductal CA

44 (84.6%)

53 (89.8%)

Invasive lobular CA

8 (15.4%)

6 (10.2%)

Tumor diameter (mm)

26.6 ± 15.9

27.0 ± 17.0

0.894

≤2 cm

22 (42.3%)

25 (42.4%)

0.508

>2–<5 (2.1–4.9 cm)

27 (51.9%)

27 (45.8%)

≥5 cm

3 (5.8%)

7 (11.9%)

I and II

35 (67.3%)

37 (62.7%)

III

17 (32.7%)

22 (37.3%)

Lymphatic canal invasion

30 (57.7%)

34 (57.6%)

0.994

Vascular invasion

6 (11.5%)

8 (13.6%)

0.749

Perinoral invasion

14 (26.9%)

20 (33.9%)

0.426

Lymphatic metastasis (yes/no)

32 (61.5%)

34 (57.6%)

0.675

Number of lymph nodes

3.7 ± 6.4

5.4 ± 9.7

0.310

(N0) absent

20 (38.5%)

25 (42.4%)

(N1) 1–3 nodes positive

19 (36.5%)

11 (18.6%)

(N2) 4–9 nodes positive

7 (13.5%)

14 (23.7%)

(N3) 10 or more

6 (11.5%)

9 (15.3%)

Extensive intraductal component

19 (36.5%)

22 (37.3%)

0.935

Perinodal invasion (yes/no)

14 (26.9%)

16 (27.1%)

0.982

ER* positivity

40 (76.9%)

44 (74.6%)

0.774

PR* positivity

41 (78.8%)

44 (74.6%)

0.596

C-erb B2 positivity

15 (28.8%)

16 (27.1%)

0.880

0.409

T

Grade
0.613

N
0.158

* ER= estrogen receptor, PR= progesterone receptor

studies have also shown that tumors expressing survivin
are resistant to the apoptosis that is induced by anticancer
drugs (Tran et al., 2002; Rödel et al., 2003). Targeting of
survivin using adenoviral antisense vectors was reported
to enhance the sensitivity of tumor cells to chemotherapy
and radiotherapy (Yamamoto et al., 2003). Clarification of
the survivin signaling pathway will provide new predictive
and prognostic information for cancer diagnosis and could

lead to the development of new therapeutic alternatives
for a variety of cancers (Altieri, 2001; Yamamoto and
Tanigawa, 2001).
High survivin expression has been detected in several
cancer types in humans, including colorectal cancer,
hepatocellular cancer, lung cancer, pancreatic cancer,
and osteosarcoma (Wang et al., 2009; Yang et al., 2009;
Theodoropoulos et al., 2010; Upadhyay et al., 2011;
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Borges et al., 2011; Srivastava et al., 2012). Survivin is also
expressed in breast cancer (Yamashita et al., 2007).
It has been suggested that the expression of survivin
is transcriptionally controlled by cell-cycle-dependent
elements located in the proximal region of the survivin
promoter and in the cell-cycle homology region (Altieri,
2001). Several nucleotide polymorphisms have been
detected in these regions of the survivin DNA sequence.
One SNP is –31G > C, which is located in the cell-cycledependent element/cell-cycle homology region repressor
binding site, 31 bp upstream from the first nucleotide of
the ATG start codon. An earlier study suggested that this
polymorphism is associated with the overexpression of
survivin at the transcriptional and translational levels (Xu
et al., 2004). Based on these earlier findings, we focused
on this SNP in the present study and investigated the
association between it and breast cancer.
Although numerous reports have described the
association between the survivin –31G > C polymorphism
and a variety of different cancers, to our knowledge, this
polymorphism has not been examined in breast cancer.
Therefore, we also compared our results with those for
other types of cancer associated with the survivin – 31G
> C polymorphism. Qin et al. (2012) reported that this
polymorphism significantly enhanced the development
and progression of renal cell carcinoma in Chinese
individuals. Upadhyay et al. (2011) reported that survivin
promoter region polymorphism (–31G > C) is associated
with susceptibility to esophageal cancer in a northern
Indian population. However, Borbely et al. (2007)
reported that this polymorphism did not increase the risk
of developing cervical cancer, and Borges et al. (2011)
found no differences in the –31G > C genotypes or allele
frequencies of patients with gastric cancer and the control
group. In our study, we found a slight difference in the
prevalence of this polymorphism in the breast cancer and
control groups, although the P value (P = 0.058) slightly
exceeded the threshold for statistical significance.
Several studies have examined the potential association
of the –31 C allele in the survivin promoter region with
susceptibility to various cancers or with prognostic cancer
markers. For example, Yazdani et al. (2012) reported that
the survivin –31G > C polymorphism was associated with
an increased risk of papillary thyroid cancer and that the
frequency of the GC + CC genotype was significantly
higher in papillary thyroid cancer patients than in the
control group. Therefore, they suggested that the C allele is
a predisposing factor for papillary thyroid cancer. In their
study, the frequency of the C allele was higher in patients
with poor prognostic factors, especially lymph-node
involvement, vascular involvement, and multifocality.
Zahedi et al. (2012) reported that the frequency of the
C allele was significantly greater in endometrial cancer
patients. In our study, the risk of developing breast cancer
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was 1.413 times greater in GC + CC patients than in GG
patients (95% CI: 1.040–1.918). The prevalence of the GC
+ CC genotype was also significantly higher in the breast
cancer group than in the control group (P = 0.023), detected
in 59% and 38% of patients, respectively. According to
these results, the presence of the C allele in the promoter
region (–31G > C) of the survivin gene has a statistically
significant effect on an individual’s susceptibility to breast
cancer. In this respect, our results are consistent with
those reported by Yazdani et al. (2012) and Zahedi et al.
(2012). However, unlike Yazdani et al. (2012), we found
no significant differences in the prevalence of the GG and
GC + CC genotypes in terms of multifocal/multicentric
breast cancer (P = 0.159), lymph-duct invasion, vascular
invasion, perineural invasion, lymphatic metastasis, or the
number of metastatic lymph nodes (P > 0.05). Gazouli et
al. (2009) reported that the C allele and the CC genotype
frequencies were significantly higher in colorectal cancer
patients than in healthy subjects (P < 0.0001). In a study of
patients with lung cancer and healthy controls with at least
one G allele, Jang et al. (2008) reported that the risk of lung
cancer was significantly lower in those with at least one G
allele than in those with the CC genotype. These authors
reported that the G allele correlated with significantly
lower promoter activity than the C allele. Yang et al. (2009)
reported that the C allele increased the risk of developing
esophageal squamous cell carcinoma, and Wang et al.
(2009) reported that the risk of developing urothelial
carcinoma was significantly greater in individuals with
the GC + CC genotype than in individuals with the GG
genotype. Consistent with the studies by Yang et al. (2009)
and Wang et al. (2009), we found that the risk of developing
breast cancer was significantly greater (by 1.413 times;
95% CI: 1.040–1.918) in individuals with the GC or CC
genotype than in individuals with the GG genotype.
Bayram et al. (2011) studied the association between
the –31G > C polymorphism and hepatocellular carcinoma
in a Turkish population, but found no difference in the
genotype distributions of patients with hepatocellular
carcinoma and cancer-free individuals. However, genetic
polymorphisms may differ among ethnic groups. Similar
to the results reported by Bayram et al. (2011), we found
that the distribution of the –31G > C polymorphism did
not differ significantly between the breast cancer and
control groups (P = 0.058) in a Turkish population.
In conclusion, in terms of survivin gene promoter
polymorphisms when compared to 31GG, (31G/C +
31CC) with polymorphisms, carrying the C allele (31GC
or 31CC) in the survivin gene promoter region was
statistically significant in terms of susceptibility to breast
cancer. Because genetic polymorphisms may differ between
ethnic groups, further studies are required to examine the
associations between polymorphisms in genes such as
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survivin and breast cancer in other ethnic populations.
The present study should provide a foundation for future
studies in this important field. To confirm our findings,
other studies of larger populations are needed. Our
results indicated that the CC homozygote genotype in the
patient group is twice as common as the CC homozygote
genotype in healthy controls in Turkish population, but
the number of all CC genotypes is 19 out of 212 cases. If
the number of cases as well as CC genotypes is increased
with further studies, results may display a tendency to
breast cancer in the CC genotype, which may be used for
diagnostic approaches. If our findings are supported by

the results of future studies, we think that the assessment
of polymorphisms in the survivin gene promoter region
may also add a new dimension to therapeutic approaches
to breast cancer. For example, we think that knowledge of
the patient’s genotype will help oncologists make better
decisions regarding the need for prophylactic mastectomy
in women with a high risk of breast cancer.
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